Genaera has reported that the first patient has been enrolled in a multicenter, open-label, pharmacodynamic Phase II clinical trial to explore the efficacy and safety of Evizon at higher doses.
The study is designed to evaluate up to 140 patients with wet age-related macular degeneration treated with Evizon at four dose levels over a 20 week period.
Evizon is a product, in development for ophthalmic indications, specifically wet age-related macular degeneration.